Time to arrhythmic, ischemic, and heart failure events: Exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial-Reference-Cited by-同舟云学术

Time to arrhythmic, ischemic, and heart failure events: Exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial

Published:1995-07 Issue:1 Volume:130 Page:71-79
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Hallstrom Alfred P.,Anderson Jeffrey L.,Carlson Mark,Davies Richard,Greene H.Leon,Kammerling James M.,Romhilt Donald W.,Duff Henry J.,Huther Melissa

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference18 articles.

1. Ventricular premature beats and mortality after myocardial infarction;Ruberman;N Engl J Med,1977

2. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction;Bigger;Circulation,1984

3. Risk factors for sudden death after myocardial infarction: two-year follow-up;Mukharji;Am J Cardiol,1984

4. Indications for antiarrhythmic therapy: a wealth of controversy, a dearth of data;Woosley;Ann Intern Med,1988

5. A classification of antiarrhythmic actions reassessed after a decade of new drugs;Vaughn Williams;J Clin Pharmacol,1984

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medications to Avoid in Acute Decompensated Heart Failure;Current Emergency and Hospital Medicine Reports;2017-04-04

2. Drugs to Avoid in Acute Decompensated Heart Failure (ADHF): Contraindicated Medications and Interactions;Contemporary Cardiology;2017

3. Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts;Europace;2014-01-30

4. Electrophysiological and Hemodynamic Effects of Vernakalant and Flecainide During Cardiac Resynchronization in Dyssynchronous Canine Hearts;Journal of Cardiovascular Pharmacology;2014-01

5. Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity;Pharmacology & Therapeutics;2013-06